KUALA LUMPUR: Duopharma Biotech Bhd
is looking at a gradual recovery in revenue as it continues to strengthen its portfolio with high-value innovative offerings and niche products.
Group managing director Leonard Ariff Abdul Shatar said the group will focus on the ethical and consumer healthcare segments, while weathering persistent industry-wide challenges.
Already a subscriber? Log in
Save 30% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
